STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices
STAT
DECEMBER 7, 2023
But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.
Let's personalize your content